BeyondSpring, Inc. (BYSI) Fair Value 2026

BYSI · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.8 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, BeyondSpring, Inc. (BYSI) trades at $1.27, approximately 1407% above CirclFi’s Bayesian DCF fair value of $0.08. QOC: 3.8/10. Value Trap Risk: 24/100 (SAFE). 10/13 models active.

Key Facts

Ticker
BYSI
Price
$1.27
Quality Score
3.8/10
Value Trap Risk
24/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +55.5% upside with 14% confidence
Risk: Below-average Quality Score of 3.8/10 signals weak fundamentals

Is BeyondSpring, Inc. (BYSI) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, BeyondSpring, Inc. (BYSI) appears overvalued as of : the median of 10 independent fair value estimates is $0.64, 49.7% below the current price of $1.27. Estimates range from $0.08 to $1.97. BYSI scores 3.8/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BeyondSpring, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($1.27)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
$0.08 -93.4%
Earnings Power Value
Medium Conviction
$0.75 -40.8%
CUCE Ensemble
Low Conviction
$0.53 -58.6%
First Chicago
Low Conviction
$1.97 +55.5%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is BeyondSpring, Inc. (BYSI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BeyondSpring, Inc.'s intrinsic value is estimated at $0.75, suggesting the stock is overvalued at its current price of $1.27. With 8 out of 10 models flagging downside (-40.9% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: First Chicago targets $1.97 (+55.5%), versus Bayesian DCF at $0.08 (-93.4%). This +148.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BYSI?

10 of 13 models are currently active for BYSI. Of these, 2 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates BYSI's intrinsic value at $0.08, implying -93.4% downside from the current price. See which stocks rank higher →

How Does BYSI Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, BYSI ranks #357 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Within the Pharmaceutical Preparations space, BeyondSpring, Inc. competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is BYSI a Value Trap?

CirclFi's Value Trap algorithm assigns BYSI a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for BeyondSpring, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BeyondSpring, Inc. is rated at 3.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +148.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BYSI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BYSI's 10 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BeyondSpring, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About BeyondSpring, Inc.

What is BeyondSpring, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, BeyondSpring, Inc. (BYSI) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.08. The Quality of Company score is 3.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BYSI overvalued or undervalued right now?

At $1.27, 2 of 10 active models suggest BYSI may be undervalued, while 8 indicate potential overvaluation. The median of all 10 fair value estimates is $0.64, 49.7% below the current price of $1.27 — a consensus view that BYSI is overvalued. The assessment depends on which methodology best fits BeyondSpring, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 3.8 mean for BYSI?

BeyondSpring, Inc.'s QOC of 3.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BYSI?

CirclFi analyzes BYSI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is BYSI a value trap in 2026?

BeyondSpring, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, BeyondSpring, Inc. (BYSI) has a median fair value of $0.64 — 49.7% below the current price of $1.27 — as of 2026-07-15.” Source: circlfi.com/stock/BYSI/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on BYSI.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access